Humoral immune response after Ad26.COV2.S vaccination in patients with multiple sclerosis treated with natalizumab

被引：0
|
作者：
Gudesblatt, Mark [1 ,2 ]
Zarif, Myassar [2 ]
Bumstead, Barbara [2 ]
Buhse, Marijean [2 ]
Kaczmarek, Olivia [2 ]
Li, Hanyue [3 ]
Sun, Zhaonan [3 ]
Scott, Nicole [3 ]
Mendoza, Jason P. [3 ]
Avila, Robin L. [3 ]
机构：
[1] Langone South Shore Neurol Associates, 77 Medford Ave, Patchogue, NY 11772 USA
[2] NYU Langone South Shore Neurol Associates PC, Patchogue, NY USA
[3] Biogen, Cambridge, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL | 2023年 / 9卷 / 04期
关键词：
Multiple sclerosis; natalizumab; COVID-19; vaccine;
D O I：
10.1177/20552173231218117
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
The immunomodulatory effects of disease-modifying therapies for multiple sclerosis might affect the immune response to vaccines for severe acute respiratory syndrome coronavirus 2. We analyzed the severe acute respiratory syndrome coronavirus 2-specific antibody response and lymphocyte profile before and after Ad26.COV2.S (Johnson & Johnson) vaccination in natalizumab-treated patients with multiple sclerosis. There was a 72-fold increase in mean anti-severe acute respiratory syndrome coronavirus 2 spike immunoglobulin G levels 4 weeks after vaccination and a 137-fold increase after 6 months. Other immune signals were within normal ranges. Natalizumab-treated patients with multiple sclerosis had a robust immune response to Ad26.COV2.S vaccine, and other immune signals were not significantly affected.
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Humoral immune response after SARS-CoV-2 vaccination in cladribine-treated multiple sclerosis patients
    Mimpen, M.
    Kreiter, D.
    Kempkens, T.
    Knippenberg, S.
    Hupperts, R.
    Gerlach, O.
    VACCINE: X, 2024, 16
  • [2] Guillain-Barre Syndrome After Ad26.COV2.S Vaccination
    Thant, Hein Linn
    Morgan, Richard
    Paese, Mario M.
    Persaud, Trevor
    Diaz, Jose
    Hurtado, Lina
    AMERICAN JOURNAL OF CASE REPORTS, 2022, 23
  • [3] Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination
    Faissner, Simon
    Heitmann, Neele
    Plaza-Sirvent, Carlos
    Trendelenburg, Paulina
    Ceylan, Ulas
    Motte, Jeremias
    Bessen, Clara
    Urlaub, Doris
    Watzl, Carsten
    Overheu, Oliver
    Reinacher-Schick, Anke
    Hellwig, Kerstin
    Pfaender, Stephanie
    Schmitz, Ingo
    Gold, Ralf
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [4] Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination
    Gelbenegger, Georg
    Cacioppo, Filippo
    Firbas, Christa
    Jilma, Bernd
    VACCINES, 2021, 9 (09)
  • [5] Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis
    Pompsch, Mosche
    Fisenkci, Neslinur
    Horn, Peter A.
    Kraemer, Markus
    Lindemann, Monika
    NEUROLOGICAL RESEARCH AND PRACTICE, 2021, 3 (01):
  • [6] Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis
    Mosche Pompsch
    Neslinur Fisenkci
    Peter A. Horn
    Markus Kraemer
    Monika Lindemann
    Neurological Research and Practice, 3
  • [7] Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab
    Katz, J. D.
    Bouley, A. J.
    Jungquist, R. M.
    Douglas, E. A.
    O'Shea, I. L.
    Lathi, E. S.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
  • [8] The Biodistribution of the Spike Protein after Ad26.COV2.S Vaccination Is Unlikely to Play a Role in Vaccine-Induced Immune Thrombotic Thrombocytopenia
    Marquez-Martinez, Sonia
    Khan, Selina
    Lubbe, Joan van der
    Solforosi, Laura
    Costes, Lea M. M.
    Choi, Ying
    Boedhoe, Satish
    Verslegers, Mieke
    Heerden, Marjolein van
    Roosen, Wendy
    Jonghe, Sandra De
    Kristyanto, Hendy
    Rezelj, Veronica
    Hendriks, Jenny
    Serroyen, Jan
    Tolboom, Jeroen
    Wegmann, Frank
    Zahn, Roland C.
    VACCINES, 2024, 12 (05)
  • [9] CCL20 chemokine and other proinflammatory markers after Ad26.COV2.S vaccination
    Ivanko, Iva
    Hanzek, Milena
    Celap, Ivana
    Margetic, Sandra
    Marijancevic, Domagoj
    Josipovic, Josipa
    Gacina, Petar
    BIOCHEMIA MEDICA, 2024, 34 (03)
  • [10] A Rare Variant of Guillain-Barre Syndrome Following Ad26.COV2.S Vaccination
    Morehouse, Zachary P.
    Paulus, Amanda
    Jasti, Sri A.
    Bing, Xue
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (09)
12345